Cardinal Health (CAH) has continually made significant initiatives in recent times. Wall Street analysts have set remarkable target prices for the company's stock, acknowledging its strong value. Recent stock performance outshines competition, but mixed Q3 results have resulted in stock decline. Despite an instance of contract non-renewal, Cardinal Health keeps its outlook positive by reaffirming fiscal 2024 non-GAAP EPS guidance and long-term targets. The company also ramps up its operations by acquiring Specialty Networks and its PPS Analytics platform. CAH's annual research report showcases a profound year in biosimilars, and it continues to top earnings and keeps leading the healthcare sector trades heavily. Moreover, CAH adds a pharmaceutical distribution center for over-the-counter products and increases its dividend, further solidifying its lead in the market. However, bearish sentiments arise from a lowered stock rating and loss of contracts with UnitedHealth's OptumRX. Clearbridge Investments LLC and Orion Portfolio Solutions LLC added more shares, which increased institutional holdings to 89%. CAH continues to enhance its portfolio, streamline operations, and publishes its Fiscal 2023 ESG report. Despite few hurdles, CAH's valuation and steady growth create a solid option for long-term investment.
Cardinal Health CAH News Analytics from Tue, 15 Aug 2023 07:00:00 GMT to Thu, 30 May 2024 01:04:06 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor 4
